122 related articles for article (PubMed ID: 37399991)
1. Identification of tau-tubulin kinase 1 inhibitors by microfluidics-based mobility shift assay from a kinase inhibitor library.
Wang J; Lin Y; Xu X; Wang Y; Xie Q
SLAS Discov; 2023 Dec; 28(8):385-393. PubMed ID: 37399991
[TBL] [Abstract][Full Text] [Related]
2. X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors.
Xue Y; Wan PT; Hillertz P; Schweikart F; Zhao Y; Wissler L; Dekker N
ChemMedChem; 2013 Nov; 8(11):1846-54. PubMed ID: 24039150
[TBL] [Abstract][Full Text] [Related]
3. Tau-tubulin kinase 1 and amyloid-β peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models.
Ikezu S; Ingraham Dixie KL; Koro L; Watanabe T; Kaibuchi K; Ikezu T
Acta Neuropathol Commun; 2020 Feb; 8(1):12. PubMed ID: 32019603
[TBL] [Abstract][Full Text] [Related]
4. A microfluidics-based mobility shift assay to identify new inhibitors of β-secretase for Alzheimer's disease.
Liu R; Liu YC; Meng J; Zhu H; Zhang X
Anal Bioanal Chem; 2017 Nov; 409(28):6635-6642. PubMed ID: 28889204
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA 00507/miRNA-181c-5p/TTBK1/MAPT axis regulates tau hyperphosphorylation in Alzheimer's disease.
Yan Y; Yan H; Teng Y; Wang Q; Yang P; Zhang L; Cheng H; Fu S
J Gene Med; 2020 Dec; 22(12):e3268. PubMed ID: 32891070
[TBL] [Abstract][Full Text] [Related]
6. Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites.
Dillon GM; Henderson JL; Bao C; Joyce JA; Calhoun M; Amaral B; King KW; Bajrami B; Rabah D
PLoS One; 2020; 15(4):e0228771. PubMed ID: 32255788
[TBL] [Abstract][Full Text] [Related]
7. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation.
Sato S; Cerny RL; Buescher JL; Ikezu T
J Neurochem; 2006 Sep; 98(5):1573-84. PubMed ID: 16923168
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice.
Yukawa K; Yamamoto-Mcguire S; Cafaro L; Hong C; Kamme F; Ikezu T; Ikezu S
Acta Neuropathol Commun; 2023 Oct; 11(1):166. PubMed ID: 37853497
[TBL] [Abstract][Full Text] [Related]
9. The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor.
Kiefer SE; Chang CJ; Kimura SR; Gao M; Xie D; Zhang Y; Zhang G; Gill MB; Mastalerz H; Thompson LA; Cacace AM; Sheriff S
Acta Crystallogr F Struct Biol Commun; 2014 Feb; 70(Pt 2):173-81. PubMed ID: 24637750
[TBL] [Abstract][Full Text] [Related]
10. Tau-tubulin kinase.
Ikezu S; Ikezu T
Front Mol Neurosci; 2014; 7():33. PubMed ID: 24808823
[TBL] [Abstract][Full Text] [Related]
11. miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3β in Alzheimer's disease.
Li J; Chen W; Yi Y; Tong Q
J Cell Biochem; 2019 Jun; 120(6):9936-9946. PubMed ID: 30556160
[TBL] [Abstract][Full Text] [Related]
12. The structural, functional, and dynamic effect of Tau tubulin kinase1 upon a mutation: A neuro-degenerative hotspot.
Ahamad S; Hema K; Kumar V; Gupta D
J Cell Biochem; 2021 Nov; 122(11):1653-1664. PubMed ID: 34297427
[TBL] [Abstract][Full Text] [Related]
13. Tau-tubulin kinase 1 expression, phosphorylation and co-localization with phospho-Ser422 tau in the Alzheimer's disease brain.
Lund H; Cowburn RF; Gustafsson E; Strömberg K; Svensson A; Dahllund L; Malinowsky D; Sunnemark D
Brain Pathol; 2013 Jul; 23(4):378-89. PubMed ID: 23088643
[TBL] [Abstract][Full Text] [Related]
14. Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1.
Sato S; Xu J; Okuyama S; Martinez LB; Walsh SM; Jacobsen MT; Swan RJ; Schlautman JD; Ciborowski P; Ikezu T
J Neurosci; 2008 Dec; 28(53):14511-21. PubMed ID: 19118186
[TBL] [Abstract][Full Text] [Related]
15. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
16. Identification of human tau-tubulin kinase 1 inhibitors: an integrated e-pharmacophore-based virtual screening and molecular dynamics simulation.
Jana S; Singh SK
J Biomol Struct Dyn; 2020 Feb; 38(3):886-900. PubMed ID: 30829560
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo.
Halkina T; Henderson JL; Lin EY; Himmelbauer MK; Jones JH; Nevalainen M; Feng J; King K; Rooney M; Johnson JL; Marcotte DJ; Chodaparambil JV; Kumar PR; Patterson TA; Murugan P; Schuman E; Wong L; Hesson T; Lamore S; Bao C; Calhoun M; Certo H; Amaral B; Dillon GM; Gilfillan R; de Turiso FG
J Med Chem; 2021 May; 64(9):6358-6380. PubMed ID: 33944571
[TBL] [Abstract][Full Text] [Related]
18. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805
[TBL] [Abstract][Full Text] [Related]
19. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Regulation and Diverse Activities of Tau-Tubulin Kinase (TTBK) Isoforms.
Bao C; Bajrami B; Marcotte DJ; Chodaparambil JV; Kerns HM; Henderson J; Wei R; Gao B; Dillon GM
Cell Mol Neurobiol; 2021 May; 41(4):669-685. PubMed ID: 32424773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
